Tariman Joseph D, Love Ginger, McCullagh Emily, Sandifer Stacey
Biobehavioral Nursing and Health Systems Department, University of Washington, Seattle, USA.
Clin J Oncol Nurs. 2008 Jun;12(3 Suppl):29-36. doi: 10.1188/08.CJON.S1.29-35.
The novel therapies thalidomide and bortezomib can cause peripheral neuropathy, a challenging adverse event that can affect quality of life and compromise optimal treatment for patients with multiple myeloma. At baseline, patients should be evaluated for signs and symptoms of peripheral neuropathy with a neurotoxicity assessment tool and educated about the symptoms and the importance of reporting them. Signs, symptoms, and the ability to perform activities of daily living should be evaluated regularly so that appropriate interventions can be employed if necessary. Specific management strategies for peripheral neuropathy are based on the grade of severity and on signs and symptoms; strategies include dose and schedule modifications, pharmacologic interventions, nonpharmacologic approaches, and patient education.
新型疗法沙利度胺和硼替佐米可导致周围神经病变，这是一种具有挑战性的不良事件，会影响生活质量并危及多发性骨髓瘤患者的最佳治疗。在基线时，应使用神经毒性评估工具对患者进行周围神经病变的体征和症状评估，并就症状及报告症状的重要性对患者进行教育。应定期评估体征、症状以及进行日常生活活动的能力，以便在必要时采取适当干预措施。周围神经病变的具体管理策略基于严重程度分级以及体征和症状；策略包括剂量和给药方案调整、药物干预、非药物方法以及患者教育。
